Clinical utility and validity of minoxidil response testing in androgenetic alopecia

被引：51

作者：

Goren, Andy ^{[1
,2
]}

Shapiro, Jerry ^{[3
]}

Roberts, Janet ^{[4
]}

McCoy, John ^{[1
]}

Desai, Nisha ^{[4
]}

Zarrab, Zoulikha ^{[2
]}

Pietrzak, Aldona ^{[5
]}

Lotti, Torello ^{[2
]}

机构：

[1] Appl Biol, Irvine, CA 92614 USA

[2] Univ Rome G Marconi, Dept Dermatol & Venereol, Rome, Italy

[3] NYU, Dept Dermatol, Langone Med Ctr, New York, NY 10016 USA

[4] Northwest Dermatol & Res Ctr, Portland, OR USA

[5] Univ Lublin, Sch Med, Lublin, Poland

来源：

DERMATOLOGIC THERAPY | 2015年 / 28卷 / 01期

关键词：

androgenetic alopecia; minoxidil; response test; TOPICAL MINOXIDIL; SULFATION; PLACEBO; TRIAL;

D O I：

10.1111/dth.12164

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Clinical response to 5% topical minoxidil for the treatment of androgenetic alopecia (AGA) is typically observed after 3-6 months. Approximately 40% of patients will regrow hair. Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have significant clinical utility. Two studies have previously reported that sulfotransferase enzyme activity in plucked hair follicles predicts a patient's response to topical minoxidil therapy. The aim of this study was to assess the clinical utility and validity of minoxidil response testing. In this communication, the present authors conducted an analysis of completed and ongoing studies of minoxidil response testing. The analysis confirmed the clinical utility of a sulfotransferase enzyme test in successfully ruling out 95.9% of nonresponders to topical minoxidil for the treatment of AGA.

引用

页码：13 / 16

页数：4

共 8 条

[1] Sulfation of minoxidil by multiple human cytosolic sulfotransferases [J].

Anderson, RJ ;

Kudlacek, PE ;

Clemens, DL .

CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 109 (1-3) :53-67

[2]

BAKER CA, 1994, SKIN PHARMACOL, V7, P335

[3] MINOXIDIL SULFATE IS THE ACTIVE METABOLITE THAT STIMULATES HAIR-FOLLICLES [J].

BUHL, AE ;

WALDON, DJ ;

BAKER, CA ;

JOHNSON, GA .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (05) :553-557

[4] Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia [J].

Goren, Andy ;

Antonio Castano, Juan ;

McCoy, John ;

Bermudez, Fernando ;

Lotti, Torello .

DERMATOLOGIC THERAPY, 2014, 27 (03) :171-173

[5]

Hoffmann R, 2000, EUR J DERMATOL, V10, P410

[6] A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men [J].

Olsen, EA ;

Dunlap, FE ;

Funicella, T ;

Koperski, JA ;

Swinehart, JM ;

Tschen, EH ;

Trancik, RJ .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) :377-385

[7] A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men [J].

Olsen, Elise A. ;

Whiting, David ;

Bergfeld, Wilma ;

Miller, Jeffrey ;

Hordinsky, Maria ;

Wanser, Rita ;

Zhang, Paul ;

Kohut, Bruce .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 57 (05) :767-774

[8] Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia [J].

Roberts, Janet ;

Desai, Nisha ;

McCoy, John ;

Goren, Andy .

DERMATOLOGIC THERAPY, 2014, 27 (04) :252-254

← 1 →